Sho Wakamatsu

The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma

Teruo Jojima, Sho Wakamatsu, Masato Kase et al. · International Journal of Molecular Sciences · 2019 · 120 citations · Full text

Immunology, Pathology, Canagliflozin Group +21

Empagliflozin increases plasma levels of campesterol, a marker of cholesterol absorption, in patients with type 2 diabetes: Association with a slight increase in high-density lipoprotein cholesterol

Teruo Jojima, Shintaro Sakurai, Sho Wakamatsu et al. · International Journal of Cardiology · 2021 · 24 citations

Metabolic Syndrome, High-density Lipoprotein Cholesterol, Cardiovascular Disease +11

Effect of growth hormone replacement therapy on plasma diacron-reactive oxygen metabolites and endothelial function in Japanese patients: The GREAT clinical study

Kunihiro Suzuki, Kazunori Yanagi, Masanori Shimizu et al. · Endocrine Journal · 2017 · 23 citations · Full text

The effects of intermittent use of the SGLT-2 inhibitor, dapagliflozin, in overweight patients with type 2 diabetes in Japan: a randomized, crossover, controlled clinical trial

Kanako Kato, Kunihiro Suzuki, Chie Aoki et al. · Expert Opinion on Pharmacotherapy · 2017 · 14 citations

Inhibition of IL-33 signaling ameliorate hepatic fibrosis with decreasing MCP-1 in a mouse model of diabetes and non-alcoholic steatohepatitis; comparison for luseogliflozin, an SGLT2 inhibitor

Sho Wakamatsu, Teruo Jojima, Masaaki Hashiguchi et al. · Journal of Diabetes and its Complications · 2023 · 10 citations · Full text